公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2017 | Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial | Nash P.; Kirkham B.; Okada M.; Rahman P.; Combe B.; Burmester G.-R.; Adams D.H.; Kerr L.; Lee C.; Shuler C.L.; Genovese M.; Ahmed K.; Alper J.; Barkham N.; Bennett R.E.; Garc?a F.J.B.; Alonso R.B.; Blumstein H.B.; Brooks M.S.; Burmester G.-R.; Cagnoli P.; Caldron P.H.; Cantagrel A.; Chen D.-Y.; Churchill M.A.; Jr, Codding C.E.; Combe B.; Deane P.M.G.; Del Giudice J.; Deodhar A.A.; Dhar R.K.; Dokoupilova E.; Egan R.M.; Everding A.; Gal?ndez E.; Genovese M.; Goddard D.H.; Gottlieb A.; Goupille P.; Griffin R.M.; Gupta R.C.; Hall S.; Hatti K.; Howell M.P.; Huang Y.-H.; Jajoo R.; Janssen N.M.; Kiltz U.; Kivitz A.J.; Klein S.J.; Korkosz M.P.; Kotha R.; Kremer J.M.; Lue C.; de la Fuente J.L.M.; Marzo-Ortega H.; Masmitja J.G.; Mease P.J.; Meroni P.L.; Mueller E.C.; Nandagudi A.C.; Nash P.; Fern?ndez-Nebro A.; Neuwelt C.M.; Orbai A.M.; Oza M.R.; Parks D.L.; Pattanaik D.; Rell-Bakalarska M.E.; Rosmarin D.; Roussou E.; Rychlewska-Hanczewksa A.I.; Sikes D.H.; Stack M.T.; Sunkureddi P.; Tahir H.; Tha?i D.; TSEN-FANG TSAI ; Turkiewicz A.M.; Unger L.; Cabello R.V.; Wagner U.; Wei C.-C.; Wells A.F.; Youssef P.; Zielinska A. | The Lancet | 314 | 294 | |
2019 | Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial | Reich K.; Gooderham M.; Tha?i D.; Crowley J.J.; Ryan C.; Krueger J.G.; TSEN-FANG TSAI ; Flack M.; Gu Y.; Williams D.A.; Thompson E.H.Z.; Paul C. | The Lancet | 191 | 157 | |
2019 | Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study | Tha?i D.; Puig L.; Reich K.; TSEN-FANG TSAI ; Tyring S.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Lacombe A.; Xia S.; Bhosekar V.; Gilloteau I.; Guana A.; Blauvelt A. | Journal of the American Academy of Dermatology | 15 | 13 | |
2015 | Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial | Tha?i D.; Blauvelt A.; Reich K.; TSEN-FANG TSAI ; Vanaclocha F.; Kingo K.; Ziv M.; Pinter A.; Hugot S.; You R.; Milutinovic M. | Journal of the American Academy of Dermatology | 467 | 418 | |
2017 | Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1?year: Results from the CLEAR study | Blauvelt A.; Reich K.; TSEN-FANG TSAI ; Tyring S.; Vanaclocha F.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Hugot S.; You R.; Milutinovic M.; Tha?i D. | Journal of the American Academy of Dermatology | 254 | 227 |